EPIX Pharmaceuticals Inc.

Dr. Gamzu joined EPIX in July 2008. Dr. Gamzu is a Principal of enERGetics Biopharmaceutical Consultancy, LLC, and was a founding partner of BioPharmAnalysis, LLC. From February 26, 2007 until January 3, 2008, Dr. Gamzu was the Chief Executive Officer of Pharmos Corporation, and from March 2005 until March 2006, Dr. Gamzu was Acting Head of Clinical Development of Hypnion, Inc. From December 1, 2004 until February 24, 2005, Dr. Gamzu was the interim CEO of XTL Biopharmaceuticals, Ltd., and from 2001 until 2002, Dr. Gamzu was Vice President of Product Management Leadership for Millennium Pharmaceuticals, Inc. Dr. Gamzu also served as President and Chief Executive Officer of Cambridge Neuroscience, Inc. from 1994 until 1998, and as President and Chief Operating Officer and Vice President of Development for Cambridge Neuroscience, Inc. from 1989 to 1994. Previously, Dr. Gamzu held a variety of senior positions with Warner-Lambert and Hoffmann-La Roche, Inc. Dr. Gamzu is a graduate of Hebrew University in Jerusalem, and has M.A. and Ph.D. degrees in experimental and physiological psychology from the University of Pennsylvania.

Ms. Drapkin brings more than 15 years of diversified and integrated corporate accounting and pharmaceutical management experience. Prior to joining EPIX, Ms. Drapkin served as Chief Financial Officer of Predix Pharmaceuticals and spent 10 years at Millennium Pharmaceuticals in senior positions of increasing responsibility within the finance organization. Ms. Drapkin has extensive experience in financial management, technical accounting, SEC reporting and Sarbanes Oxley compliance. Prior to joining Millennium, Ms. Drapkin served as an auditor in the technology and life sciences audit practice at PricewaterhouseCoopers LLP, Boston. Ms. Drapkin is a graduate of Babson College, holding a B.S. in accounting (Summa Cum Laude) and she is a Certified Public Accountant (CPA).

Ms. Sousa joined the company in June 1998. She came to EPIX from RKS Health Ventures and the Spence Center for Women's Health where she was the Director of Human Resources from June 1995 to May 1998. Prior to 1998, Ms. Sousa spent ten years in the hospitality industry with Hilton, Stouffers and Sonesta Hotels in a variety of sales and marketing positions. She is a member of the Board of Directors for a nonprofit organization, Career Collaborative, and is the Chair of their Employer Advisory Committee.

Dr. McMurry is a Founder of Ascent and serves as Vice President, Preclinical R&D. He was previously Vice President of Research at EPIX Pharmaceuticals where he gained experience in drug discovery and drove the expansion of the Company's proprietary technology platform into new areas. Dr. McMurry joined EPIX in March 1993 as Director, Synthetic Chemistry and held positions of increasing seniority during his thirteen year tenure with the Company, including Executive Director of Discovery and Intellectual Property. From 1987 to 1993, Dr. McMurry was a Fellow at the National Institute of Health. Dr. McMurry is a graduate of the Pennsylvania State University and holds a Ph.D. in Chemistry from the University of Michigan. He performed his postdoctoral studies at the University of California, Berkeley.

Mr. Phelps is the Chairman of the Board, President, and Chief Executive Officer of RenaMed Biologics, Inc., a biotechnology company developing therapeutic products. He has previously held positions of Chief Executive Officer of Ardais Corporation, Viagene, Inc. and ZymoGenetics, Inc. He has also served as Vice Chairman of Dyax Corporation, Executive Vice President of Genzyme Corporation and Vice President of Baxter Travenol Laboratories, Inc. (now Baxter Healthcare).

Mr. Smith is Senior Vice President and CFO of Vertex Pharmaceuticals Inc., a publicly traded biotechnology company. Prior to joining Vertex, Mr. Smith was a Partner with Ernst & Young LLP, where he served as a Partner in the Life Science and Technology practice. Mr. Smith received a B.A. with honors in accounting and finance from Manchester Metropolitan University, U.K., is a member of the American Institute of Certified Public Accountants and is a Chartered Accountant of England and Wales.

Mr. Leuchtenberger became President and Chief Executive Officer of Targanta Therapeutics, a privately held NDA stage antibiotics company, in 2006. Mr. Leuchtenberger joined Targanta from Therion Biologics Corporation, a privately held cancer vaccine company, where he served as President and Chief Executive Officer from 2002 to 2006. Under his leadership, Therion filed its first IND, progressed through Phase 3 trials, completed the buildup of its commercial manufacturing capabilities, and raised over $120 million in three rounds of private financings. Prior to joining Therion in 2002, Mr. Leuchtenberger spent 11 years at Biogen, Inc., where he led the development and launch of Avonex and ran North American and international commercial operations. Prior to Biogen, he was a consultant at Bain & Company specializing in healthcare. Mr. Leuchtenberger also serves on boards for the Massachusetts Biotechnology Council, Beth Israel Deaconess Medical Center and Wake Forest University.

Michael Gilman, Ph.D. is President and CEO of Stromedix, Inc. and most recently served as Executive Vice President of Research at Biogen Idec, Inc. During his six-year tenure at Biogen Idec, from 1999 to 2005, Dr. Gilman managed discovery research including inflammatory and autoimmune diseases, and cancer. From 1994 to 1999, Dr. Gilman served as Executive Vice President and Chief Scientific Officer of Ariad Pharmaceuticals Inc. where he was responsible for drug discovery activities to develop novel gene- and cell-regulation technologies. Earlier in his career, Dr. Gilman was a principal investigator at Cold Spring Harbor Laboratory where he ran an active research programs in growth control and cancer, signal transduction and gene transcription and held adjunct academic appointments at SUNY Stony Brook. He earned a Ph.D. in Biochemistry from the University of California, Berkeley, and holds an S.B. in Life Sciences from the Massachusetts Institute of Technology.

Peter Wirth joined Genzyme in 1996 after having served as the company’s outside general counsel since 1982. He has senior management responsibility for the corporate development and legal departments. Prior to joining Genzyme, he was a partner at Palmer and Dodge, a Boston law firm, where he was head of the firm’s technology group. Mr. Wirth has a J.D. from Harvard Law School and a B.A. from the University of Wisconsin.